Back to today’s briefing

Story perspectives

Promising ALS Treatment IFB-088 Shows Reduced Progression

2/11/2025

40 4

Summary

Story summary

A Phase 2 trial of the oral therapy IFB-088 has revealed promising results for bulbar-onset ALS patients, demonstrating safety and a potential slowdown in disease progression. Inflectis Bioscience reported that patients taking IFB-088 experienced less loss of functionality compared to those on a placebo, paving the way for further research into its effectiveness in combating ALS.

1 of 1

Story summary

A Phase 2 trial of the oral therapy IFB-088 has revealed promising results for bulbar-onset ALS patients, demonstrating safety and a potential slowdown in disease progression. Inflectis Bioscience reported that patients taking IFB-088 experienced less loss of functionality compared to those on a placebo, paving the way for further research into its effectiveness in combating ALS.